Advertising for compounded GLP-1 weight loss products is facing increased scrutiny as regulators respond to the rapid expansion of telehealth marketing across the U.S.
In late 2025, multiple regulatory and self-regulatory bodies signaled a shift toward closer oversight of how compounded GLP-1 drugs are promoted to consumers. The concern is not the existence of compounded medications, but whether advertising accurately reflects their regulatory status, evidence base, and limitations.
This article explains what is changing, why it matters, and how recent enforcement actions fit into a broader pattern across the GLP-1 market.
Key Facts
- U.S. regulators are increasing scrutiny of advertising for compounded GLP-1 weight loss products.
- The National Advertising Division reviewed multiple telehealth claims involving compounded semaglutide and tirzepatide.
- Willow Health was referred to state and federal authorities after declining to modify advertising claims.
- Regulators found claims relied on studies of FDA-approved drugs, not compounded versions.
- The FDA and FTC have issued guidance and enforcement actions related to GLP-1 marketing.
A broader regulatory pattern is taking shape
Recent actions show that compounded GLP-1 advertising is no longer being treated as a gray area.
The National Advertising Division (NAD) of BBB National Programs has reviewed multiple cases involving compounded semaglutide and tirzepatide products. In these cases, NAD evaluated whether advertising claims related to safety, effectiveness, and weight loss outcomes were supported by evidence. In several instances, NAD recommended that companies discontinue or modify claims when substantiation was lacking [1][2].
At the federal level, the Federal Trade Commission has also stepped in. In December 2025, the FTC finalized an order against a telehealth company accused of using deceptive advertising practices related to GLP-1 weight loss programs. The order required clearer disclosures and prohibited misleading claims about pricing and outcomes [3].
Legal analyses published in 2025 also show increased coordination between the FDA, FTC, and HHS around digital advertising for compounded drugs sold through telehealth platforms [4].
Together, these actions suggest a clear regulatory trend toward tighter enforcement.
What regulators are focusing on
Across agencies and review bodies, several consistent concerns appear.
Regulators are challenging advertising that:
- Implies compounded GLP-1 products are equivalent to FDA approved drugs
- Suggests proven safety or effectiveness without supporting evidence
- Uses clinical data from brand-name drugs to justify claims for compounded versions
- Minimizes or obscures the fact that compounded products are not FDA approved
FDA guidance has long required that prescription drug promotion be truthful and not misleading. In 2025, the agency reiterated that compounded drugs are not exempt from these standards simply because they are prescribed through telehealth [4]. Telehealth companies should always consider ethical guidelines when promoting a GLP-1 medication.
These concerns are not theoretical. Advertising language plays a real role in how patients interpret safety, effectiveness, and risk when considering compounded GLP-1 options.
The Willow decision in context
One of the most visible cases involved Willow Health Services, a telehealth company marketing compounded semaglutide products in tablet and injectable forms.
Following a challenge brought by Novo Nordisk, NAD reviewed Willow’s express and implied claims related to safety, effectiveness, and weight loss benefits. NAD determined that Willow did not provide adequate evidence to support many of these claims. In particular, NAD found that studies of FDA approved semaglutide products could not substantiate claims for compounded alternatives that differ in formulation and method of administration [1].
NAD recommended that Willow discontinue or modify the challenged advertising. When Willow declined to confirm compliance, NAD announced it would refer the matter to state and federal regulatory authorities [1].
This referral aligns with similar NAD cases involving other providers of compounded GLP-1 products reviewed throughout 2025 [2].
Why this matters for consumers
The compounded GLP-1 market expanded rapidly during shortages of FDA approved drugs. Many consumers turned to compounded options because of cost, access, or availability.
However, compounded drugs are not FDA approved. They do not undergo the same premarket clinical review process, and their safety and effectiveness are not evaluated in the same way as brand-name GLP-1 medications. We break down these differences in more detail in our guide comparing compounded GLP-1s vs brand-name GLP-1s.
A 2025 study from Yale School of Medicine found that online advertising for compounded diabetes and weight loss drugs often lacked clear disclosures and sometimes implied regulatory approval where none existed. In some cases, ads omitted basic safety information altogether [5].
The FDA has also issued warnings about unapproved GLP-1 products sold online, including compounded and research-only versions of semaglutide and tirzepatide. The agency cautioned that these products may pose safety risks or contain incorrect ingredients [6].
What comes next
Regulatory scrutiny of compounded GLP-1 advertising is expected to continue.
Between NAD referrals, FTC enforcement actions, and FDA guidance, companies marketing compounded weight loss drugs are being pushed to tighten claims and clarify what their products are and are not.
For consumers, the takeaway is straightforward. Advertising claims do not equal regulatory approval, and compounded medications should not be assumed to carry the same assurances as FDA approved drugs. Understanding those differences is becoming more important as the GLP-1 market continues to evolve.
This is a developing story, stay tuned at GLP1Remedy for the latest!
Sources
- [1] Willow Health Services Inc. (Compounded Semaglutide Products), Report #7488, NAD/CARU Case Reports (November 2025); Better Business Bureau, National Advertising Division Will Refer Willow Health to State and Federal Regulatory Authorities for its Compounded Semaglutide Product Claims (December 4, 2025).
https://bbbprograms.org/media/newsroom/decisions/willow-health - [2] NAD/CARU Case Reports involving compounded GLP-1 advertising, including Regen Doctors, Fletcher Family Medical Center, Striker Pharmacy, Begin Anew MedSpa, and Hormone Fitness (2025). https://bbbprograms.org/media/newsroom/decisions
- [3] Federal Trade Commission. FTC Approves Final Order Against Telehealth Provider for Deceptive GLP-1 Advertising (December 2025).
https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive - [4] Holland & Knight. FDA and HHS Increase Enforcement of Compounded Drug Advertising (September 2025).
https://www.hklaw.com/en/insights/publications/2025/09/fda-hhs-taking-action-against-telehealths-compounded-drug-advertising - [5] Yale School of Medicine. Study Finds Online Advertising for Compounded Diabetes and Weight Loss Drugs May Mislead Consumers (2025).
https://medicine.yale.edu/news-article/new-study-finds-online-advertising-for-compounded-diabetes-and-weight-loss-drugs-may-mislead-consumers/ - [6] U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
